Clinical trials are the engine of progress in breast cancer, but they are slow and costly. AI changes that: it helps screen patient records to find eligible participants, reads trial imaging with consistent criteria and analyses endpoints earlier and more precisely.
The result: trials that finish faster, cost less and produce cleaner data. Faster trials mean new treatments reach women sooner — and AI-assisted analysis surfaces signals of benefit or harm earlier.
How AI accelerates trials
- Automating patient eligibility screening
- Consistent AI reading of imaging endpoints
- Early, precise analysis of response data
- Discovering the patient subgroups that benefit most